Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature o...

Descripción completa

Detalles Bibliográficos
Autores principales: Szponar, Paweł, Petrasz, Piotr, Brzeźniakiewicz-Janus, Katarzyna, Drewa, Tomasz, Zorga, Piotr, Adamowicz, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687416/
https://www.ncbi.nlm.nih.gov/pubmed/38033494
http://dx.doi.org/10.3389/fonc.2023.1239118
_version_ 1785151973321867264
author Szponar, Paweł
Petrasz, Piotr
Brzeźniakiewicz-Janus, Katarzyna
Drewa, Tomasz
Zorga, Piotr
Adamowicz, Jan
author_facet Szponar, Paweł
Petrasz, Piotr
Brzeźniakiewicz-Janus, Katarzyna
Drewa, Tomasz
Zorga, Piotr
Adamowicz, Jan
author_sort Szponar, Paweł
collection PubMed
description INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA. METHODS: We performed a scoping literature review of PubMed from January 1996 to December 2022. RESULTS: 98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides. CONCLUSION: Radioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care.
format Online
Article
Text
id pubmed-10687416
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106874162023-11-30 Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review Szponar, Paweł Petrasz, Piotr Brzeźniakiewicz-Janus, Katarzyna Drewa, Tomasz Zorga, Piotr Adamowicz, Jan Front Oncol Oncology INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature on the therapeutic isotopes specific for PSMA. METHODS: We performed a scoping literature review of PubMed from January 1996 to December 2022. RESULTS: 98 publications were selected for inclusion in this review. The studies contained in publications allowed to summarize the data on pharmacokinetics, therapeutic effects, side effects and the medical use of 225Ac and 177Lu radionuclides. The review also presents new research directions for specific PSMA radionuclides. CONCLUSION: Radioligand targeted therapy is a new and promising concept where Lu-177-PSMA-617 have promising outcomes in treatment according to standard of care. Frontiers Media S.A. 2023-11-16 /pmc/articles/PMC10687416/ /pubmed/38033494 http://dx.doi.org/10.3389/fonc.2023.1239118 Text en Copyright © 2023 Szponar, Petrasz, Brzeźniakiewicz-Janus, Drewa, Zorga and Adamowicz https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Szponar, Paweł
Petrasz, Piotr
Brzeźniakiewicz-Janus, Katarzyna
Drewa, Tomasz
Zorga, Piotr
Adamowicz, Jan
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title_full Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title_fullStr Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title_full_unstemmed Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title_short Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
title_sort precision strikes: psma-targeted radionuclide therapy in prostate cancer – a narrative review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687416/
https://www.ncbi.nlm.nih.gov/pubmed/38033494
http://dx.doi.org/10.3389/fonc.2023.1239118
work_keys_str_mv AT szponarpaweł precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview
AT petraszpiotr precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview
AT brzezniakiewiczjanuskatarzyna precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview
AT drewatomasz precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview
AT zorgapiotr precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview
AT adamowiczjan precisionstrikespsmatargetedradionuclidetherapyinprostatecanceranarrativereview

Ejemplares similares